Compare · ALXN vs CATB
ALXN vs CATB
Side-by-side comparison of Alexion Pharmaceuticals, Inc. (ALXN) and Catabasis Pharmaceuticals, Inc. (CATB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALXN and CATB operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- CATB has more recent analyst coverage (2 ratings vs 0 for ALXN).
- Company
- Alexion Pharmaceuticals, Inc.
- Catabasis Pharmaceuticals, Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1996
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 2
CATB
Catabasis Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company's lead product candidate is QLS-215, a monoclonal antibody inhibitor of plasma kallikrein that is in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. The company was incorporated in 2008 and is based in Boston, Massachusetts.
Latest ALXN
- Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer
- SEC Form 15-12G filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.
Latest CATB
- SEC Form SC 13D/A filed by Catabasis Pharmaceuticals, Inc. (Amendment)
- SEC Form 4 filed by Violin Jonathan
- SEC Form SC 13G/A filed by Catabasis Pharmaceuticals, Inc. (Amendment)
- Catabasis Pharmaceuticals, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus
- Wedbush initiated coverage on Catabasis Pharmaceuticals with a new price target
- Catabasis Pharmaceuticals upgraded by HC Wainwright & Co. with a new price target
- Catabasis Pharmaceuticals, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form S-8 filed by Catabasis Pharmaceuticals, Inc.
- Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update